1
Observed incidence of second malignancy did not significantly exceed expected incidence.
2
However, patients receiving RT do not have significantly elevated cumulative incidence of second malignancy.
3
The development of a second malignancy is almost always fatal.
4
One patient refused therapy and died of the second malignancy.
5
One patient died in CR due to the second malignancy.
6
Background: The leading cause of death among patients with hereditary retinoblastoma is second malignancy.
7
Possible explanations include genetic abnormalities, environmental exposures or immune-related mechanisms predisposing to the second malignancy.
8
The incidence and related mortality of a second malignancy or recurrence of thymoma were recorded.
9
Another died of a second malignancy on day 2232.
10
Surveillance of extrapancreatic malignancies might also provide opportunities to detect early-stage PDAC as a second malignancy.
11
No patient developed a second malignancy during follow-up.
12
The clinically pertinent meanings of simultaneous, synchronous, and metachronous second malignancy of the lung are presented.
13
At a median follow-up 10.5 years, 709 patients had developed a second malignancy.
14
All patients were alive and no patient developed a second malignancy at a median follow up of 25 months.
15
During follow-up, 12 patients had a recurrence of thymoma and 14 developed a second malignancy.
16
Renal neoplasia occurring as a second malignancy following childhood cancer has been most closely associated with neuroblastoma and Wilms tumor.
